Meeting
2023 ASCO Annual Meeting
T cell receptor-engineered T cells targeting a human endogenous retrovirus in kidney cancer.
Authors
Stefan Barisic
Laboratory of Transplantation Immunotherapy, Cellular and Molecular Therapeutics Branch, NHLBI, NIH, Bethesda, MD
Stefan Barisic , Elizabeth M. Brahmbhatt , Elena Cherkasova , Rosa Nadal , Ujjawal Savani , Stephanie Pierre , Long Chen , Timothy T. Spear , Gina M. Scurti , Gang Zeng , Gordon Parry , David F. Stroncek , Steven L. Highfill , Annika V. Dalheim , Robert N. Reger , Michael I. Nishimura , Richard W. Childs
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4542)
DOI
10.1200/JCO.2023.41.16_suppl.4542
Abstract #
4542
Poster Bd #
34
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase I results of human endogenous retrovirus type-E (HERV-E) TCR transduced T-cells in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Identification of HLA-A0201 restricted epitope of novel cancer/testis antigens VCX/Y and generation of antigen-specific T-cell receptor engineered T cells for treatment of solid tumor malignancies.
First Author: Ke Pan
Poster
2024 ASCO Genitourinary Cancers Symposium
Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).
First Author: Rosa Nadal
Poster
2019 ASCO Annual Meeting
Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.
First Author: Marcus O. Butler